Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Canon invests in T2 Biosystems
by Marc S. Reisch
October 3, 2016
| A version of this story appeared in
Volume 94, Issue 39
Canon USA has purchased a nearly 20% stake in T2 Biosystems, a maker of time-domain nuclear magnetic resonance diagnostics, for $40 million. T2 has worked with the molecular diagnostics arm of Canon since 2015 to develop a test panel for Lyme disease. T2 expects to use the funds to grow its business and launch a sepsis detection panel in 2017. The firm’s technology was developed by scientists at Massachusetts General Hospital and MIT.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter